| pubmed-article:10942053 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C0040732 | lld:lifeskim |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C0019829 | lld:lifeskim |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C2347678 | lld:lifeskim |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C2347880 | lld:lifeskim |
| pubmed-article:10942053 | lifeskim:mentions | umls-concept:C0338248 | lld:lifeskim |
| pubmed-article:10942053 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10942053 | pubmed:dateCreated | 2001-3-8 | lld:pubmed |
| pubmed-article:10942053 | pubmed:abstractText | The use of autologous peripheral blood progenitor cells (PBPC) expedites hematologic recovery and reduces the costs of transplantation in comparison with autologous bone marrow; however, its efficacy in patients with Hodgkin's disease has been questioned. We evaluated the results of autologous PBPC transplantation in a population of unselected and uniformly treated patients with primary refractory or relapsed Hodgkin's disease. | lld:pubmed |
| pubmed-article:10942053 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10942053 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10942053 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10942053 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10942053 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10942053 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10942053 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10942053 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10942053 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10942053 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10942053 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10942053 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:10942053 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:10942053 | pubmed:author | pubmed-author:CooperD LDL | lld:pubmed |
| pubmed-article:10942053 | pubmed:author | pubmed-author:SeropianSS | lld:pubmed |
| pubmed-article:10942053 | pubmed:author | pubmed-author:ArgirisAA | lld:pubmed |
| pubmed-article:10942053 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10942053 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:10942053 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10942053 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10942053 | pubmed:pagination | 665-72 | lld:pubmed |
| pubmed-article:10942053 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:meshHeading | pubmed-meshheading:10942053... | lld:pubmed |
| pubmed-article:10942053 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10942053 | pubmed:articleTitle | High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. | lld:pubmed |
| pubmed-article:10942053 | pubmed:affiliation | Section of Medical Oncology, Yale University-School of Medicine, New Haven, Connecticut 06520, USA. athanassios@pol.net | lld:pubmed |
| pubmed-article:10942053 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10942053 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10942053 | lld:pubmed |
